Mineralocorticoid receptor activation and blockade: An emerging paradigm in chronic kidney disease

Kidney International

Volumn 79, Issue 10, 2011, Pages 1051-1060

  Bertocchio, Jean Philippe ^a   Warnock, David G ^b   Jaisser, Frederic ^a  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

aldosterone; kidney diseases; mineralocorticoid; proteinuria; receptors

Indexed keywords

ALDOSTERONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CILAZAPRIL; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; SPIRONOLACTONE;

ABSENCE OF SIDE EFFECTS; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; GYNECOMASTIA; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPERTENSIVE NEPHROPATHY; IMMUNOLOCALIZATION; KIDNEY DISEASE; KIDNEY FAILURE; NEPHROTOXICITY; NONHUMAN; PATHOGENESIS; PEDIATRICS; PREGNANCY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEINURIA; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; SODIUM DEPLETION; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 79955622277     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.48     Document Type: Review

References (119)

1. Conn JW. Presidential address I.Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 1955; 45: 3-17.
2. Conn JW, Knopf RF, Nesbit RM. Clinical characteristics of primary Aldosteronism from an analysis of 145 Cases. Am J Surg 1964; 107: 159-172.
3. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996; 98: 1063-1068. (Pubitemid 26293326)
4. Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 2001; 345: 925-926.
5. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717. (Pubitemid 29407370)
6. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321. (Pubitemid 36384098)
7. Zannad F, McMurray JJV, Krum H et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2010; 364: 11-21.
8. Bonvalet JP. Regulation of sodium transport by steroid hormones. Kidney Int Suppl 1998; 65: S49-S56.
9. Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology 2000; 47: 119-125. (Pubitemid 30394535)
10. Calne RY, White DJ, Thiru S et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 1978; 2: 1323-1327. (Pubitemid 9078430)
11. Viengchareun S, Le Menuet D, Martinerie L et al. The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology. Nucl Recept Signal 2007; 5: e012.
12. Farman N, Rafestin-Oblin ME. Multiple aspects of mineralocorticoid selectivity. Am J Physiol Renal Physiol 2001; 280: F181-F192.
13. Arriza JL, Weinberger C, Cerelli G et al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 1987; 237: 268-275. (Pubitemid 17095145)
14. Meneton P, Loffing J, Warnock DG. Sodium and potassium handling by the aldosterone-sensitive distal nephron: the pivotal role of the distal and connecting tubule. Am J Physiol Renal Physiol 2004; 287: F593-F601. (Pubitemid 39280492)
15. Nguyen Dinh Cat A, Griol-Charhbili V, Loufrani L et al. The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure. FASEB J 2010; 24: 2454-2463.
16. Funder JW. The role of aldosterone and mineralocorticoid receptors in cardiovascular disease. Am J Cardiovasc Drugs 2007; 7: 151-157. (Pubitemid 47047985)
17. Gekle M, Grossmann C. Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly? Pflugers Arch 2009; 458: 231-246.
18. Robert V, Silvestre JS, Charlemagne D et al. Biological determinants of aldosterone-induced cardiac fibrosis in rats. Hypertension 1995; 26: 971-978.
19. Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 1992; 120: 893-901. (Pubitemid 23002899)
20. Funder JW. Mineralocorticoid receptor activation and oxidative stress. Hypertension 2007; 50: 840-841. (Pubitemid 350287521)
21. Guo C, Ricchiuti V, Lian BQ et al. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation 2008; 117: 2253-2261.
22. Kosugi T, Heinig M, Nakayama T et al. eNOS knockout mice with advanced diabetic nephropathy have less benefit from reninangiotensin blockade than from aldosterone receptor antagonists. Am J Pathol 2010; 176: 619-629.
23. Taira M, Toba H, Murakami M et al. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats. Eur J Pharmacol 2008; 589: 264-271.
24. Quinkler M, Zehnder D, Eardley KS et al. Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria. Circulation 2005; 112: 1435-1443. (Pubitemid 41291769)
25. Ohtani T, Ohta M, Yamamoto K et al. Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: beneficial effects of mineralocorticoid receptor blocker. Am J Physiol Regul Integr Comp Physiol 2007; 292: R946-R954. (Pubitemid 46207752)
26. Nagata K, Obata K, Xu J et al. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension 2006; 47: 656-664. (Pubitemid 43740235)
27. Takeda M, Tatsumi T, Matsunaga S et al. Spironolactone modulates expressions of cardiac mineralocorticoid receptor and 11betahydroxysteroid dehydrogenase 2 and prevents ventricular remodeling in post-infarct rat hearts. Hypertens Res 2007; 30: 427-437. (Pubitemid 46958893)
28. de Resende MM, Kauser K, Mill JG. Regulation of cardiac and renal mineralocorticoid receptor expression by captopril following myocardial infarction in rats. Life Sci 2006; 78: 3066-3073.
29. DeLano FA, Schmid-Schonbein GW. Enhancement of glucocorticoid and mineralocorticoid receptor density in the microcirculation of the spontaneously hypertensive rat. Microcirculation 2004; 11: 69-78. (Pubitemid 39618607)
30. Krug AW, Allenhofer L, Monticone R et al. Elevated mineralocorticoid receptor activity in aged rat vascular smooth muscle cells promotes a proinflammatory phenotype via extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase and epidermal growth factor receptordependent pathways. Hypertension 2010; 55: 1476-1483.
31. Tada Y, Kitazato KT, Tamura T et al. Role of mineralocorticoid receptor on experimental cerebral aneurysms in rats. Hypertension 2009; 54: 552-557.
32. Iwashima F, Yoshimoto T, Minami I et al. Aldosterone induces superoxide generation via Rac1 activation in endothelial cells. Endocrinology 2008; 149: 1009-1014. (Pubitemid 351397957)
33. Shibata S, Nagase M, Yoshida S et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med 2008; 14: 1370-1376.
34. Stanisic V, Lonard DM, O'Malley BW. Modulation of steroid hormone receptor activity. Prog Brain Res 2010; 181: 153-176.
35. Di Zhang A, Cat AN, Soukaseum C et al. Cross-talk between mineralocorticoid and angiotensin II signaling for cardiac remodeling. Hypertension 2008; 52: 1060-1067.
36. Montezano AC, Touyz RM. Networking between systemic angiotensin II and cardiac mineralocorticoid receptors. Hypertension 2008; 52: 1016-1018.
37. Jain G, Campbell RC, Warnock DG. Mineralocorticoid receptor blockers and chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 1685-1691.
38. Schrier RW. Hyperkalemia: a threat to RAAS inhibition? Nat Rev Nephrol 2010; 6: 245-246.
39. Gomez-Sanchez CE, de Rodriguez AF, Romero DG et al. Development of a panel of monoclonal antibodies against the mineralocorticoid receptor. Endocrinology 2006; 147: 1343-1348. (Pubitemid 43244368)
40. Nishiyama A, Yao L, Fan Y et al. Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability. Hypertension 2005; 45: 710-716. (Pubitemid 40418370)
41. Nagai Y, Miyata K, Sun GP et al. Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1/2 in rat renal fibroblasts. Hypertension 2005; 46: 1039-1045.
42. Lee SH, Yoo TH, Nam BY et al. Activation of local aldosterone system within podocytes is involved in apoptosis under diabetic conditions. Am J Physiol Renal Physiol 2009; 297: F1381-F1390.
43. Nagase M, Yoshida S, Shibata S et al. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol 2006; 17: 3438-3446. (Pubitemid 44865286)
44. Rocha R, Stier Jr CT, Kifor I et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000; 141: 3871-3878.
45. Rocha R, Rudolph AE, Frierdich GE et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002; 283: H1802-H1810. (Pubitemid 35217013)
46. Kobayashi N, Hara K, Tojo A et al. Eplerenone shows renoprotective effect by reducing LOX-1-mediated adhesion molecule, PKCepsilon- MAPK-p90RSK, and Rho-kinase pathway. Hypertension 2005; 45: 538-544. (Pubitemid 40411256)
47. Chun TY, Chander PN, Kim JW et al. Aldosterone, but not angiotensin II, increases profibrotic factors in kidney of adrenalectomized stroke-prone spontaneously hypertensive rats. Am J Physiol Endocrinol Metab 2008; 295: E305-E312.
48. Whaley-Connell A, Habibi J, Wei Y et al. Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat. Am J Physiol Renal Physiol 2009; 296: F1013-F1022.
49. Nagase M, Shibata S, Yoshida S et al. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 2006; 47: 1084-1093. (Pubitemid 44289165)
50. Chander PN, Rocha R, Ranaudo J et al. Aldosterone plays a pivotal role in the pathogenesis of thrombotic microangiopathy in SHRSP. J Am Soc Nephrol 2003; 14: 1990-1997. (Pubitemid 36909906)
51. Quan ZY, Walser M, Hill GS. Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level. Kidney Int 1992; 41: 326-333.
52. Aldigier JC, Kanjanbuch T, Ma LJ et al. Regression of existing glomerulosclerosis by inhibition of aldosterone. J Am Soc Nephrol 2005; 16: 3306-3314. (Pubitemid 46187550)
53. Gullulu M, Akdag I, Kahvecioglu S et al. Aldosterone blockage in proliferative glomerulonephritis prevents not only fibrosis, but proliferation as well. Ren Fail 2006; 28: 509-514. (Pubitemid 44277677)
54. Nakhoul F, Khankin E, Yaccob A et al. Eplerenone potentiates the antiproteinuric effects of enalapril in experimental nephrotic syndrome. Am J Physiol Renal Physiol 2008; 294: F628-F637. (Pubitemid 351442234)
55. Monrad SU, Killen PD, Anderson MR et al. The role of aldosterone blockade in murine lupus nephritis. Arthritis Res Ther 2008; 10: R5.
56. Sun GP, Kohno M, Guo P et al. Involvements of Rho-kinase and TGF-beta pathways in aldosterone-induced renal injury. J Am Soc Nephrol 2006; 17: 2193-2201. (Pubitemid 44141909)
57. Fujisawa G, Okada K, Muto S et al. Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. Kidney Int 2004; 66: 1493-1502. (Pubitemid 39298382)
58. Yuan J, Jia R, Bao Y. Beneficial effects of spironolactone on glomerular injury in streptozotocin-induced diabetic rats. J Renin Angiotensin Aldosterone Syst 2007; 8: 118-126. (Pubitemid 350148448)
59. Han SY, Kim CH, Kim HS et al. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol 2006; 17: 1362-1372.
60. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009; 4: 481-508.
61. Nankivell BJ, Borrows RJ, Fung CL et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326-2333. (Pubitemid 37509740)
62. Bobadilla NA, Gamba G. New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone. Am J Physiol Renal Physiol 2007; 293: F2-F9. (Pubitemid 47345003)
63. Heinze G, Mitterbauer C, Regele H et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 2006; 17: 889-899.
64. Bantle JP, Boudreau RJ, Ferris TF. Suppression of plasma renin activity by cyclosporine. Am J Med 1987; 83: 59-64. (Pubitemid 18099027)
65. Lassila M. Interaction of cyclosporine A and the renin-angiotensin system; new perspectives. Curr Drug Metab 2002; 3: 61-71. (Pubitemid 34296310)
66. Perez-Rojas JM, Derive S, Blanco JA et al. Renocortical mRNA expression of vasoactive factors during spironolactone protective effect in chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol 2005; 289: F1020-F1030. (Pubitemid 41447057)
67. Perez-Rojas J, Blanco JA, Cruz C et al. Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol 2007; 292: F131-F139. (Pubitemid 46105252)
68. Feria I, Pichardo I, Juarez P et al. Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney Int 2003; 63: 43-52. (Pubitemid 35463905)
69. Waanders F, Rienstra H, Boer MW et al. Spironolactone ameliorates transplant vasculopathy in renal chronic transplant dysfunction in rats. Am J Physiol Renal Physiol 2009; 296: F1072-F1079.
70. Nielsen FT, Jensen BL, Marcussen N et al. Inhibition of mineralocorticoid receptors with eplerenone alleviates short-term cyclosporin A nephrotoxicity in conscious rats. Nephrol Dial Transplant 2008; 23: 2777-2783.
71. Ruggenenti P, Perna A, Mosconi L et al. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. 'Gruppo Italiano di Studi Epidemiologici in Nefrologia' (GISEN). Kidney Int 1998; 53: 1209-1216. (Pubitemid 28316881)
72. Pitt B. 'Escape' of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther 1995; 9: 145-149.
73. Schjoedt KJ, Andersen S, Rossing P et al. Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 2004; 47: 1936-1939. (Pubitemid 40110201)
74. Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007; 3: 486-492. (Pubitemid 47313030)
75. Sato A, Hayashi K, Naruse M et al. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41: 64-68. (Pubitemid 36056793)
76. Ku E, Campese VM. Role of aldosterone in the progression of chronic kidney disease and potential use of aldosterone blockade in children. Pediatr Nephrol 2009; 24: 2301-2307.
77. Okubo S, Niimura F, Nishimura H et al. Angiotensin-independent mechanism for aldosterone synthesis during chronic extracellular fluid volume depletion. J Clin Invest 1997; 99: 855-860. (Pubitemid 27123621)
78. Miao Y, Dobre D, Lambers Heerspink HJ et al. Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. Diabetologia 2010; 54: 44-50.
79. Spä t A, Hunyady L. Control of aldosterone secretion: a model for convergence in cellular signaling pathways. Physiol Rev 2004; 84: 489-539.
80. Hollenberg NK. Aldosterone in the development and progression of renal injury. Kidney Int 2004; 66: 1-9. (Pubitemid 38870076)
81. Rossi GP, Bernini G, Desideri G et al. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension 2006; 48: 232-238. (Pubitemid 44309817)
82. Hene RJ, Boer P, Koomans HA et al. Plasma aldosterone concentrations in chronic renal disease. Kidney Int 1982; 21: 98-101. (Pubitemid 12135754)
83. Epstein M, Williams GH, Weinberger M et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006; 1: 940-951.
84. Epstein FH. Spironolactone and ACE inhibition in chronic renal failure. N Engl J Med 2002; 346: 456-457. (Pubitemid 34437708)
85. Navaneethan SD, Nigwekar SU, Sehgal AR et al. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009; 4: 542-551.
86. Sato A, Hayashi K, Saruta T. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 2005; 18: 44-49. (Pubitemid 40187348)
87. Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 2006; 70: 2116-2123. (Pubitemid 44871374)
88. Chrysostomou A, Pedagogos E, MacGregor L et al. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 2006; 1: 256-262.
89. Furumatsu Y, Nagasawa Y, Tomida K et al. Effect of renin- angiotensinaldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Hypertens Res 2008; 31: 59-67. (Pubitemid 351325616)
90. Bianchi S, Bigazzi R, Campese VM. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am J Kidney Dis 2005; 46: 45-51. (Pubitemid 40848432)
91. Rachmani R, Slavachevsky I, Amit M et al. The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. Diabet Med 2004; 21: 471-475. (Pubitemid 38608536)
92. Schjoedt KJ, Rossing K, Juhl TR et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 2005; 68: 2829-2836. (Pubitemid 43251030)
93. Schjoedt KJ, Rossing K, Juhl TR et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 2006; 70: 536-542. (Pubitemid 44141580)
94. van den Meiracker AH, Baggen RG, Pauli S et al. Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function. J Hypertens 2006; 24: 2285-2292. (Pubitemid 44611039)
95. Takebayashi K, Matsumoto S, Aso Y et al. Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. J Clin Endocrinol Metab 2006; 91: 2214-2217. (Pubitemid 43855008)
96. Bomback AS, Kshirsagar AV, Amamoo MA et al. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 2008; 51: 199-211.
97. Tylicki L, Rutkowski P, Renke M et al. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an openlabel crossover randomized controlled trial. Am J Kidney Dis 2008; 52: 486-493.
98. Ando K, Ohtsu H, Arakawa Y et al. Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria. Hypertens Res 2010; 33: 616-621.
99. Nitta K, Akiba T, Nihei H. Aldosterone blockade and vascular calcification in hemodialysis patients. Am J Med 2003; 115: 250. (Pubitemid 37338154)
100. Gross E, Rothstein M, Dombek S et al. Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients. Am J Kidney Dis 2005; 46: 94-101. (Pubitemid 40848437)
101. Vukusich A, Kunstmann S, Varela C et al. A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients. Clin J Am Soc Nephrol 2010; 5: 1380-1387.
102. Saudan P, Mach F, Perneger T et al. Safety of low-dose spironolactone administration in chronic haemodialysis patients. Nephrol Dial Transplant 2003; 18: 2359-2363. (Pubitemid 37336825)
103. Hussain S, Dreyfus DE, Marcus RJ et al. Is spironolactone safe for dialysis patients? Nephrol Dial Transplant 2003; 18: 2364-2368. (Pubitemid 37336826)
104. Ponda MP, Hostetter TH. Aldosterone antagonism in chronic kidney disease. Clin J Am Soc Nephrol 2006; 1: 668-677.
105. Michea L, Vukusich A, Gonzalez M et al. Effect of spironolactone on K(+) homeostasis and ENaC expression in lymphocytes from chronic hemodialysis patients. Kidney Int 2004; 66: 1647-1653. (Pubitemid 39298401)
106. Matsumoto Y, Kageyama S, Yakushigawa T et al. Long-term low-dose spironolactone therapy is safe in oligoanuric hemodialysis patients. Cardiology 2009; 114: 32-38.
107. Hausmann MJ, Liel-Cohen N. Aldactone therapy in a peritoneal dialysis patient with decreased left ventricular function. Nephrol Dial Transplant 2002; 17: 2035-2036. (Pubitemid 35277114)
108. Chua D, Lo A, Lo C. Spironolactone use in heart failure patients with end-stage renal disease on hemodialysis: is it safe? Clin Cardiol 2010; 33: 604-608.
109. Kaito H, Nozu K, Iijima K et al. The effect of aldosterone blockade in patients with Alport syndrome. Pediatr Nephrol 2006; 21: 1824-1829. (Pubitemid 44741159)
110. Buck ML. Clinical experience with spironolactone in pediatrics. Ann Pharmacother 2005; 39: 823-828. (Pubitemid 40570659)
111. Juurlink DN, Mamdani MM, Lee DS et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351: 543-551. (Pubitemid 39025171)
112. Ritz E, Koleganova N. Aldosterone in uremia-beyond blood pressure. Blood Purif 2010; 29: 111-113.
113. Schepkens H, Vanholder R, Billiouw JM et al. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med 2001; 110: 438-441.
114. Ko DT, Juurlink DN, Mamdani MM et al. Appropriateness of spironolactone prescribing in heart failure patients: a population-based study. J Card Fail 2006; 12: 205-210.
115. Epstein M. Aldosterone receptor blockade and the role of eplerenone: evolving perspectives. Nephrol Dial Transplant 2003; 18: 1984-1992. (Pubitemid 37220302)
116. Funder JW. Eplerenone in chronic renal disease: the EVALUATE trial. Hypertens Res 2010; 33: 539-540.
117. Weir MR, Rolfe M. Potassium homeostasis and renin-angiotensinaldosterone system inhibitors. Clin J Am Soc Nephrol 2010; 5: 531-548.
118. Einhorn LM, Zhan M, Hsu VD et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med 2009; 169: 1156-1162.
119. Korgaonkar S, Tilea A, Gillespie BW et al. Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study. Clin J Am Soc Nephrol 2010; 5: 762-769.